Kura Oncology (NASDAQ:KURA) Stock Price Up 3.9%

Kura Oncology, Inc. (NASDAQ:KURA)’s share price rose 3.9% on Wednesday . The company traded as high as $20.95 and last traded at $20.95. Approximately 64,472 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 950,172 shares. The stock had previously closed at $20.16.

Analyst Ratings Changes

KURA has been the topic of a number of recent analyst reports. Stifel Nicolaus reduced their price objective on shares of Kura Oncology from $28.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. JMP Securities reissued a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Monday, September 9th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $30.60.

Kura Oncology Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. The firm has a market capitalization of $1.55 billion, a P/E ratio of -9.29 and a beta of 0.84. The stock’s 50 day simple moving average is $20.30 and its 200 day simple moving average is $20.63.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. During the same quarter in the prior year, the company earned ($0.53) EPS. The firm’s revenue for the quarter was up .0% on a year-over-year basis. As a group, analysts expect that Kura Oncology, Inc. will post -2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Quarry LP bought a new position in shares of Kura Oncology during the second quarter valued at approximately $196,000. Alethea Capital Management LLC boosted its stake in shares of Kura Oncology by 2.4% during the second quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock valued at $5,475,000 after purchasing an additional 6,300 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after purchasing an additional 1,976 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Kura Oncology by 251.5% during the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after purchasing an additional 58,422 shares in the last quarter. Finally, Armistice Capital LLC boosted its stake in shares of Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after purchasing an additional 302,000 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.